Article info

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Authors

  1. Correspondence to Dr Richard A Furie, Division of Rheumatology, Northwell Health, 865 Northern Boulevard Suite 302, Great Neck, NY 11021, USA; RFurie{at}northwell.edu
View Full Text

Citation

Furie RA, Aroca G, Cascino MD, et al
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Publication history

  • Received June 3, 2021
  • Accepted July 28, 2021
  • First published October 6, 2021.
Online issue publication 
January 04, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.